This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.
|Original language||English (US)|
|Number of pages||21|
|Journal||Endocrinology and metabolism clinics of North America|
|State||Published - Dec 1 2007|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism